Status:
RECRUITING
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
University of California, Berkeley
Conditions:
Pancreatic Cancer
Pancreatic Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.
Eligibility Criteria
Inclusion
- Cohort 1
- Age ≥18 years
- Biopsy-proven PDAC
- Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic)
- Willing and able to comply with the requirements of the protocol
- Willing to use their bluetooth-enabled wifi or cellular mobile device
- Hemoglobin A1c (HbA1c) \> 7%, or fructosamine \> 287 mg/dL, or random glucose \> 180 mg/dL, or strong clinical suspicion that patient has hyperglycemia, making it reasonable to expect their mean daily glucose is ≥154 mg/dL
- Eastern Cooperative Oncology Group performance status ≤2
- BMI \<30 kg/m2
- Cohort 2a
- Age ≥18 years
- Biopsy-proven PDAC
- Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic pancreatic cancer)
- Clinical diagnosis of diabetes mellitus
- Active care at MSK (defined as at least 1 physician or APP encounter every 3 months) for PDAC during the period from which data were recorded in the electronic medical record (in this retrospective study patients need not be under active care at the time the research is conducted)
- At least 1 electronic prescription for a sulfonylurea (glipizide, glimepiride, or glyburide) or metformin
- Three-month baseline period before metformin or sulfonylurea initiation in which the participant does not receive either drug class or insulin
- Body weight recorded within 3 months before start of metformin or a sulfonylurea
- Cohort 2b
- Age ≥18 years
- Biopsy-proven PDAC
- Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic)
- Active care at MSK (defined as at least 1 physician or APP encounter every 3 months) for PDAC during the period of data collection
- Apparent current use based on chart review of metformin (but not sulfonylurea); sulfonylurea (but not metformin); or neither drug
Exclusion
- Cohort 1
- Use during the past month of any antidiabetic medication other than metformin at home (sporadic use \[fewer than 1 of 7 days during the past month\] is permitted)
- Changes in metformin dose in the past month
- History of sulfonylurea intolerance or allergy
- History of severe hypoglycemia (hypoglycemia requiring emergency medical assistance, emergency room or urgent care visit, or hospital admission)
- AST or ALT \>3 x upper limit of normal
- Glomerular filtration rate \<30 mL/min/1.73m2
- Daily chronic use of any dose of corticosteroids (as distinct from intermittent exposure to steroids as part of cyclic chemotherapy)
- Inability to wear CGM
- Cohort 2a
- Greater than trace ascites documented on imaging or physical exam
- Cohort 2b
- Greater than trace ascites documented on imaging or physical exam
Key Trial Info
Start Date :
December 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 5 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06168812
Start Date
December 5 2023
End Date
December 5 2026
Last Update
October 20 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
2
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, United States, 07748
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
4
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack, New York, United States, 11725